Dorzolamide

Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1].

Product Specifications

CAS Number

[120279-96-1]

Product Name Alternative

L671152; MK507

UNSPSC

12352005

Hazard Statement

H302

Target

Carbonic Anhydrase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Dorzolamide.html

Solubility

10 mM in DMSO

Smiles

O=S(C(S1)=CC2=C1S([C@@H](C)C[C@@H]2NCC)(=O)=O)(N)=O

Molecular Formula

C10H16N2O4S3

Molecular Weight

324.44

Precautions

P264-P270-P330-P501

References & Citations

[1]J Biollaz, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol. 1995;47 (5) :455-60.|[2]Sangly P Srinivas, et al. Inhibition of carbonic anhydrase activity in cultured bovine corneal endothelial cells by dorzolamide. Invest Ophthalmol Vis Sci. 2002 Oct;43 (10) :3273-8.|[3]Belal M Ali, et al. Dorzolamide synergizes the antitumor activity of mitomycin C against Ehrlich's carcinoma grown in mice: role of thioredoxin-interacting protein. Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388 (12) :1271-82.